Assessment of Humoral Immunity to Measles Virus in Cancer Survivor Children after Chemotherapy: A Case-Control Study

References

• Ge YL, Zhai XW, Zhu YF, Wang XS, Xia AM, Li YF, Zeng M. Measles outbreak in pediatric hematology and oncology patients in Shanghai, 2015. Chin Med J (Engl)). 2017;130(11):1320–6. doi:10.4103/0366-6999.206358.
   PubMed Web of Science ®Google Scholar
• Toret E, Yel SE, Suman M, Duzenli Kar Y, Ozdemir ZC, Dinleyici M, Bor O. Immunization status and re-immunization of childhood acute lymphoblastic leukemia survivors. Hum Vaccines Immunotherapeutics. 2021;17(4):1132–4. doi:10.1080/21645515.2020.1802975.
   PubMed Web of Science ®Google Scholar
• Leung W, Neale G, Behm F, Iyengar R, Finkelstein D, Kastan MB, Pui CH. Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiol. 2010;34(3):303–8. doi:10.1016/j.canep.2010.03.008.
   PubMed Web of Science ®Google Scholar
• Aytac S, Yalcin SS, Cetin M, Yetgin S, Gumruk F, Tuncer M, Yurdakok K, Gurgey A. Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2010;27(5):333–43. doi:10.3109/08880011003767720.
   PubMed Web of Science ®Google Scholar
• Zhang L, Thornton CP, Ruble K, Cooper SL. Post-chemotherapy titer status and need for revaccination after treatment for childhood cancer. Clin Pediatr (Phila)). 2020;59(6):606–13. doi:10.1177/0009922820915884.
   PubMed Web of Science ®Google Scholar
• Fayea NY, Fouda AE, Kandil SM. Immunization status in childhood cancer survivors: A hidden risk which could be prevented. Pediatr Neonatol. 2017;58(6):541–5. doi:10.1016/j.pedneo.2016.04.003.
   PubMed Web of Science ®Google Scholar
• Cesaro S, Giacchino M, Fioredda F, Barone A, Battisti L, Bezzio S, Frenos S, De Santis R, Livadiotti S, Marinello S, et al. Guidelines on vaccinations in paediatric haematology and oncology patients. BioMed Res Int. 2014;2014:1–10. doi:10.1155/2014/707691.
   Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–100. doi:10.1093/cid/cit684.
   PubMed Web of Science ®Google Scholar
• Yildirim ZK, Buyukavci M. Assessment of humoral immunity to hepatitis B, measles, rubella, and mumps in children after chemotherapy. J Pediatr Hematol Oncol. 2018;40(2):e99–e102. doi:10.1097/MPH.0000000000001072.
   PubMed Web of Science ®Google Scholar
• Viana SS, Araujo GS, Faro GB, Cruz-Silva LL, Araújo-Melo CA, Cipolotti R. Antibody responses to Hepatitis B and measles-mumps-rubella vaccines in children who received chemotherapy for acute lymphoblastic leukemia. Rev Bras Hematol Hemoter. 2012;34(4):275–9. doi:10.5581/1516-8484.20120071.
   PubMedGoogle Scholar
• Fioredda F, Cavillo M, Banov L, Plebani A, Timitilli A, Castagnola E. Immunization after the elective end of antineoplastic chemotherapy in children. Pediatr Blood Cancer. 2009;52(2):165–8. doi:10.1002/pbc.21864.
   PubMed Web of Science ®Google Scholar
• Crawford NW, Heath JA, Buttery JP. Immunisation practices of paediatric oncologists: an Australasian survey. J Paediatr Child Health. 2007;43(9):593–6. doi:10.1111/j.1440-1754.2007.01162.x.
   PubMed Web of Science ®Google Scholar
• Garonzi C, Balter R, Tridello G, Pegoraro A, Pegoraro M, Pacenti M, Scattolo N, Cesaro S. The impact of chemotherapy after pediatric malignancy on humoral immunity to vaccine-preventable diseases. Mediterr J Hematol Infect Dis. 2020;12(1):e2020014. doi:10.4084/mjhid.2020.014.
   PubMedGoogle Scholar
• Perkins JL, Harris A, Pozos TC. Immune dysfunction after completion of childhood leukemia therapy. J Pediatr Hematol Oncol. 2017;39(1):1–5. doi:10.1097/MPH.0000000000000697.
   PubMed Web of Science ®Google Scholar
• Fouda AE, Kandil SM, Boujettif F, Salama YS, Fayea NY. Humoral immune response of childhood acute lymphoblastic leukemia survivors against the measles, mumps, and rubella vaccination. Hematology. 2018;23(9):590–5. doi:10.1080/10245332.2018.1460035.
   PubMed Web of Science ®Google Scholar
• de de la Fuente Garcia I, Coïc L, Leclerc JM, Laverdière C, Rousseau C, Ovetchkine P, Tapiéro B. Protection against vaccine preventable diseases in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017;64(2):315–20. doi:10.1002/pbc.26187. Epub 2016 Oct 8. PMID: 27718310.
   PubMed Web of Science ®Google Scholar
• Patel SR, Ortín M, Cohen BJ, Borrow R, Irving D, Sheldon J, Heath PT. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis. 2007;44(5):635–42. doi:10.1086/511636.
   PubMed Web of Science ®Google Scholar
• Nilsson A, De Milito A, Engström P, Nordin M, Narita M, Grillner L, Chiodi F, Björk O. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics. 2002;109(6):e91. doi:10.1542/peds.109.6.e91.
   PubMed Web of Science ®Google Scholar
• Speckhart S. Ashley. Measles titers in long-term childhood cancer survivors. Costas T. Lambrew Research Retreat. 2020:73. https://knowledgeconnection.mainehealth.org/lambrew-retreat-2020/73.
   Google Scholar
• Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, Small T. Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Disease Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and Prevention. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44(8):521–6. doi:10.1038/bmt.2009.263.
   PubMed Web of Science ®Google Scholar
• Pickering LK, Baker CJ, Freed GL, Gall SA, Grogg SE, Poland GA, Rodewald LE, Schaffner W, Stinchfield P, Tan L, et al. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(6):817–40. doi:10.1086/605430.
   PubMed Web of Science ®Google Scholar
• Bochennek K, Allwinn R, Langer R, Becker M, Keppler OT, Klingebiel T, Lehrnbecher T. Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer. Vaccine. 2014;32(27):3357–61. doi:10.1016/j.vaccine.2014.04.042.
   PubMed Web of Science ®Google Scholar
• Esposito S, Prada E, Lelii M, Castellazzi L. Immunization of children with secondary immunodeficiency. Hum Vaccin Immunother. 2015;11(11):2564–70. doi:10.1080/21645515.2015.1039208. Epub 2015 Jul 15. PMID: 26176360; PMCID: PMC4685680.
   PubMed Web of Science ®Google Scholar